Karen Ling
Karen Ling's purchase track record
Karen Ling has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/19/2026 | BLCO | $71K | -8.5% | -2.5% | +11.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.
Transaction History
| IRTC | ▲ Buy | Grant | 1,573 | $0 | 5/27/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 15,842 | $250K | 5/26/2026 | View on chart |
| BLCO | ▲ Buy | Open Market | 4,000 | $71K | 2/19/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 4,000 | $0 | 2/19/2026 | View on chart |
| IRTC | ▲ Buy | Grant | 1,358 | $0 | 5/28/2025 | View on chart |
| BLCO | ▲ Buy | Grant | 20,338 | $0 | 5/27/2025 | View on chart |
| BLCO | ▲ Buy | Grant | 14,696 | $0 | 8/2/2024 | View on chart |
| IRTC | ▲ Buy | Grant | 1,841 | $0 | 5/29/2024 | View on chart |
| BLCO | ▲ Buy | Grant | 2,642 | $0 | 3/5/2024 | View on chart |
| IRTC | ▲ Buy | Grant | 1,164 | $0 | 5/24/2023 | View on chart |
| TXMD | ▲ Buy | Option Exercise | 1,984 | — | 8/18/2022 | View on chart |
| IRTC | ▲ Buy | Grant | 653 | $0 | 5/26/2022 | View on chart |
| IRTC | ▲ Buy | Grant | 4,320 | $0 | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
iRhythm Reports Data Breach and Completes VitalConnect Acquisition
iRhythm disclosed unauthorized access to patient data, a significant security event for a healthcare company. The firm also completed the acquisition of VitalConnect to expand its cardiac monitoring platform across various care settings. Analyst views remain mixed, with Wells Fargo lowering its price target to $150 while Needham raised its target to $194.
iRhythm Reports Data Breach and Completes VitalConnect Acquisition. iRhythm disclosed unauthorized access to patient data, a significant security event for a healthcare company. The firm also completed the acquisition of VitalConnect to expand its cardiac monitoring platform across various care settings. Analyst views remain mixed, with Wells Fargo lowering its price target to $150 while Needham raised its target to $194.